Shandong Xinhua Pharmaceutical Company Limited announced that Mr. Du Deping has tendered his resignation as an executive director and the general manager of the Company and has ceased to be a member of each of the Strategic Development Committee and Nomination Committee of the Board, an alternate authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and all positions in the subsidiaries of the Company, all with effect from 1 July 2022. Mr. Du has demonstrated dedication and diligence in serving the Company during his tenure as an executive director and the general manager of the Company. The Board would like to express its gratitude to Mr. Du for his contributions to the Company.

Following the resignation of Mr. Du, he no longer holds any position in the Company. Following Mr. Du's resignation as the Alternate Authorised Representative, the Company still has two authorised representatives, Mr. Zhang Daiming and Mr. Cao Changqiu, and will be able to meet the requirements under Rule 3.05 of the Listing Rules. The Company is in the process of identifying a suitable candidate to fill the vacancy of Alternate Authorised Representative caused by the resignation of Mr. Du, and will publish further announcement once such appointment is confirmed.